CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 45 enrolled
Drug / intervention
levosimendan at a dose of 3 mcg/kg +2 moredrug
Likely dose
levosimendan at a dose of 3 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04599816
NCT04599816N/ACompleted
CompareCT.gov

Levosimendan Administration in High Risk Cardiac Surgery Patients With Pulmonary Hypertension

Aretaieion University Hospital·interventional·Posted Oct 23, 2020·Updated Feb 8, 2023

In Brief

A clinical study evaluating levosimendan at a dose of 3 mcg/kg, levosimendan at a dose of 6 mcg/kg, and 1 other intervention for Hypertension, Pulmonary and 2 related conditions. Completed, enrolled 45 participants across 1 site.

Detailed Summary

The aim of the study is to examine the pharmacokinetics and pharmacodynamic properties of Levosimendan in cardiac surgery patients with pulmonary hypertension and impaired right ventricular function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Pulmonary, Cardiac Failure, Pulmonary Vascular Resistance Abnormality
CountriesGreece
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedOct 23, 2020
Enrollment StartOct 17, 2020
Primary CompletionOct 17, 2022
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 5.7 years ago

Interventions

levosimendan at a dose of 3 mcg/kgdrug

levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction

levosimendan at a dose of 6 mcg/kgdrug

levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction

levosimendan at a dose of 12 mcg/kgdrug

levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction